ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT01704378

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Launched by NOVO NORDISK A/S · Oct 8, 2012

Download PDF Apply for Trial

Trial Information

Current as of April 24, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Signed informed consent obtained before any trial-related activities
  • • Completed the trial BIAsp-1236
  • Exclusion Criteria:
  • • Planned changes in use of any prescription medication that may interfere with glucose regulation
  • • Known or suspected allergy to trial products or related products
  • • Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures
  • • Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator

Trial Officials

Global Clinical Registry (GCR, 1452)

Study Director

Novo Nordisk A/S

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.

Locations

Kuopio, , Finland

Wirral, Merseyside, , United Kingdom

Notodden, , Norway

Falun, , Sweden

Motala, , Sweden

Gjøvik, , Norway

Kongsvinger, , Norway

Edinburgh, , United Kingdom

Hull, , United Kingdom

Liverpool, , United Kingdom

Derby, , United Kingdom

Kotka, , Finland

Lahti, , Finland

Horten, , Norway

Kirkenær, , Norway

Helsingborg, , Sweden

Scarborough, , United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials